Evogene (NASDAQ:EVGN) Stock Price Crosses Below 200 Day Moving Average – Here’s What Happened

Evogene Ltd. (NASDAQ:EVGN) shares passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.66 and traded as low as $0.95. Evogene shares last traded at $0.97, with a volume of 13,963 shares.

Analysts Set New Price Targets

Several research firms have recently commented on EVGN. StockNews.com started coverage on shares of Evogene in a research report on Saturday. They set a “sell” rating for the company. Alliance Global Partners reissued a “buy” rating on shares of Evogene in a research note on Friday, March 7th.

Evogene Stock Down 2.6 %

The business’s 50-day moving average is $1.31 and its two-hundred day moving average is $1.66. The company has a market capitalization of $5.20 million, a P/E ratio of -0.22 and a beta of 1.37.

Evogene (NASDAQ:EVGN) last announced its earnings results on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.78. The firm had revenue of $1.61 million for the quarter, compared to the consensus estimate of $3.63 million. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%. During the same quarter in the previous year, the business earned ($1.30) EPS.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evogene stock. Jane Street Group LLC purchased a new position in Evogene Ltd. (NASDAQ:EVGN) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 21,345 shares of the biotechnology company’s stock, valued at approximately $40,000. Jane Street Group LLC owned about 0.40% of Evogene as of its most recent filing with the Securities and Exchange Commission. 10.40% of the stock is owned by institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.